HR Execs on the Move

Corcept Therapeutics

www.corcept.com

 
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.corcept.com
  • 149 Commonwealth Dr
    Menlo Park, CA USA 94025
  • Phone: 650.327.3270

Executives

Name Title Contact Details
Steven Ross
 Vice President Human Resources Profile
Steven Ross
 Sr Director, Human Resources Profile
Amy Flood
 Chief Human Resources and Communications Officer Profile
Sandra Estremera-Zink
 Senior Director, Legal and Compliance Operations Profile

Similar Companies

Jamol Laboratories

Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc is a Baudette, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TYRX

TYRX is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.